fluorouracil

Figure 2 shows that 5-FU significantly (P < 0.05) reduced the salivary rate (0.50 [+ or -] 0.38) compared with the saline group (3.17 [+ or -] 1.22).

For the experiments, which examined the effect of ME combined with 5-FU on cell viability, DMEM was replaced with 90 [micro]L of each ME mixed with 10 [micro]L of 5-FU.

Patient's warts were injected intralesionally with 0.1ml/cm2 of 5-FU (50mg/ml), at the base of each wart, after cleansing the area with isopropyl alcohol.

IC50-of 5-FU was 11.843 mg/ml, its value was not significantly different from Davoodi et al., that showed IC50 of 5-FU after 48 h treatment to HCT-116 was 10 [micro]g/ml.

5-FU drug release from copoly(AMP/AAm) nanohydrogels was studied.

5-FU has been found to be an agent that may cause direct reversible cardiac toxicity or exacerbate the cause of myocardial dysfunction.

The cell viability was evaluated by the cytotoxicity test and fluorescent microscopy in order to compare the effects produced on oral fibroblasts by green AgNPs and the presence and absence of 5-FU as the functionalization agent on the nanomaterials.

After synchronization using serum-free RPMI 1640 culture medium, ARPE-19 cells were incubated with 0.05, 0.5, or 5 mg/mL 5-Fu; 0.0002, 0.002, or 0.02 mg/mL MMC; 0.025, 0.25, or 2.5 mg/mL BVZ; 0.05, 0.5, or 5 mg/mL 5-Fu + 2.5 mg/mL BVZ; 0.0002, 0.002, or 0.02 mg/mL MMC + 2.5 mg/mL BVZ; or PBS as the control for 24 h, after which they were washed with PBS.

The drug sustained-release experiment was studied under different conditions (pH 7.4 at 37[degrees]C and pH 5.6 at 37[degrees]C), and the 5-Fu released concentration was determined by HPLC.

Control group had only complete medium; DMSO group, a final concentration of 0.1 % DMSO (solvent) in complete medium; Licofelone group, treated with 10, 50, 100, 150, 200 and 250 uM licofelone for 24 or 48 h and 5-FU group, 10, 50, 100, 150, 200 and 250 uM 5-FU applied for 24 or 48 h.

However, for different fluorouracil, such as 5-FU and S-1, the effect of DPD on them will be discrepant because of the existence of CDHP.

S-1 is an oral anticancer agent containing tegafur, a prodrug of 5-fluorouracil (5-FU), and two modulators.

Anticancer drugs were as follows: 5-fluorouracil (5-FU) (WAKO, Tokyo, Japan); Irinotecan (LC Laboratories, Woburn, MA, USA).

The mice received SLPE at 0.1mg/kg (oral gavage), fluorouracil (5-Fu) at 25mg/kg (intraperitoneal injection), or SLPE and 5-Fu for 17 days.

Our team first established the rat repair model of tracheal injury caused by 5-Fu [20-23] and found that, after being treated with 5-Fu, proliferating tracheal epithelium showed degeneration and necrosis, and the residual G0 cells in the basement membrane expressed embryonic stem cell-related genes such as Oct3/4, Sox2, and Nanog.